Results: Eighteen patients were treated (15 with gli-oblastoma multiforme, two with anaplastic astrocytoma, and one with malignant glioma). None of the 18 patients demonstrated a partial or complete response. Two patients exhibited stable disease for 12 weeks before their tumors progressed. Three patients demonstrated stable disease for 6, 12, and 18 weeks before discontinuing therapy because of hematopoietic toxicity. Twelve patients experienced reversible> grade 3 hematopoietic toxicity. There was no difference in halflives (0.56 0.21 hour v 0.54 0.20 hour) or area under the curve values (4.8 1.7 g/mL/h v 5.0 1.3 g/mL/h) of O6-BG for patients receiving phenytoin and those not treated with this drug.

Conclusion: These results indicate that O6-BG plus